» Articles » PMID: 34090999

Extracellular Vesicles in Cancer Progression

Overview
Specialty Oncology
Date 2021 Jun 6
PMID 34090999
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells release a variety of factors that contribute to the alteration of proximal and distal tissues to promote metastasis. Recent studies have demonstrated that aggressive cancer cells release extracellular vesicles with higher protein content and in excess than extracellular vesicles isolated from patients with less aggressive disease or healthy individuals. We found that melanoma tumor-derived extracellular vesicles (TEV) downregulate type I interferon receptor subunit 1 (IFNAR1), suppress expression of the interferon stimulated gene cholesterol 25-hydroxylase (CH25H). Loss of CH25H is observed in the leukocytes from melanoma patients, which correlated with metastasis and poor survival. Similarly, mice also exhibit loss of IFNAR1 following TEV administration. Moreover, loss of CH25H increased TEV uptake and TEV-induced pre metastatic niche and lung metastasis. Use of the anti-hypertensive drug, reserpine, mimicked the effects of the CH25H product 25-hydroxycholesterol to suppress TEV uptake and TEV-mediated tumor growth, pre-metastatic niche formation, and lung metastasis. These results suggest the importance of CH25H in suppressing TEV mediate cancer progression and importance of developing strategies to suppress TEV uptake and TEV-mediated disease progression.

Citing Articles

CH25H Promotes Autophagy and Regulates the Malignant Progression of Laryngeal Squamous Cell Carcinoma Through the PI3K-AKT Pathway.

Xiang Z, Yu S, Xu Y, Xiong H, Hu D, Li Q Cancer Med. 2024; 13(20):e70312.

PMID: 39428922 PMC: 11491687. DOI: 10.1002/cam4.70312.


Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.

Jaime-Casas S, Tripathi A, Pal S, Yip W Curr Urol Rep. 2024; 26(1):11.

PMID: 39379745 PMC: 11461588. DOI: 10.1007/s11934-024-01245-1.


Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway.

Li Y, Fan L, Yan A, Ren X, Zhao Y, Hua B J Transl Med. 2024; 22(1):112.

PMID: 38282047 PMC: 10823750. DOI: 10.1186/s12967-024-04914-4.


Extracellular vesicle-mediated ferroptosis, pyroptosis, and necroptosis: potential clinical applications in cancer therapy.

Yang Y, Jiang Q, Yang K, Wang L, Sethi G, Ma Z Cell Death Discov. 2024; 10(1):23.

PMID: 38216595 PMC: 10786909. DOI: 10.1038/s41420-024-01799-6.


Resistin Induces Migration and Invasion in PC3 Prostate Cancer Cells: Role of Extracellular Vesicles.

Oregel-Cortez M, Frayde-Gomez H, Quintana-Gonzalez G, Garcia-Gonzalez V, Vazquez-Jimenez J, Galindo-Hernandez O Life (Basel). 2023; 13(12).

PMID: 38137922 PMC: 10744490. DOI: 10.3390/life13122321.


References
1.
Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View

2.
Ostrowski M, Carmo N, Krumeich S, Fanget I, Raposo G, Savina A . Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2009; 12(1):19-30. DOI: 10.1038/ncb2000. View

3.
Mulcahy L, Pink R, Carter D . Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014; 3. PMC: 4122821. DOI: 10.3402/jev.v3.24641. View

4.
Ortiz A, Fuchs S . Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine. 2016; 89:4-11. PMC: 4959969. DOI: 10.1016/j.cyto.2016.01.010. View

5.
Peinado H, Lavotshkin S, Lyden D . The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21(2):139-46. DOI: 10.1016/j.semcancer.2011.01.002. View